Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Sold by Millennium Management LLC

Millennium Management LLC decreased its position in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 91.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,337 shares of the company’s stock after selling 450,889 shares during the quarter. Millennium Management LLC owned about 0.59% of Kezar Life Sciences worth $291,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of Kezar Life Sciences by 613.8% during the fourth quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock worth $80,000 after purchasing an additional 10,219 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Kezar Life Sciences during the fourth quarter worth $217,000. BML Capital Management LLC acquired a new stake in shares of Kezar Life Sciences during the fourth quarter worth $327,000. Finally, Peapod Lane Capital LLC acquired a new stake in shares of Kezar Life Sciences during the fourth quarter worth $833,000. Institutional investors and hedge funds own 67.90% of the company’s stock.

Wall Street Analyst Weigh In

Separately, William Blair reaffirmed an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th.

Kezar Life Sciences Stock Up 5.2%

NASDAQ:KZR opened at $4.68 on Wednesday. The firm has a market capitalization of $34.19 million, a price-to-earnings ratio of -0.36 and a beta of 0.58. Kezar Life Sciences, Inc. has a 1-year low of $3.62 and a 1-year high of $9.18. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.05. The business’s fifty day moving average price is $4.22 and its 200 day moving average price is $5.55.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($2.27) earnings per share for the quarter, beating the consensus estimate of ($2.56) by $0.29. On average, sell-side analysts forecast that Kezar Life Sciences, Inc. will post -4.39 earnings per share for the current fiscal year.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.